New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
14:42 EDTALNY, NVS, TKMR, ARWRAlnylam slips after Novartis reportedly cuts back RNAi development
Shares of Alnylam (ALNY) are lower in afternoon trading after a biotech focused newsletter reported that its partner, pharmaceutical giant Novartis (NVS), confirmed plans to "significantly reduce" its ribonucleic acid interface, or RNAi, research efforts. WHAT'S NEW: FierceBiotech reported earlier today that Novartis has decided to significantly cut back its once-ambitious RNAi research efforts, citing ongoing problems associated with delivering these therapies and the small number of relevant targets they could target. A total of 26 Novartis staffers were working full-time on the RNAi program full time, which grew out of a partnership with Alnylam, the report noted. OTHERS TO WATCH: Tekmira Pharmaceuticals (TKMR), like Alnylam, is focused on advancing ribonucleic acid interference therapeutics. Arrowhead Research (ARWR) is another biopharmaceutical company developing RNAi therapeutics. PRICE ACTION: In afternoon trading, Alnylam shares are down 4.5% to $52.58, Tekmira's stock is down nearly 16% to $15.49, and Arrowhead shares are off 3% to $12.71. Shares of Novartis are up about 1% to $83.48.
News For ALNY;NVS;TKMR;ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 24, 2014
07:31 EDTARWRArrowhead management to meet with Deutsche Bank
Subscribe for More Information
October 23, 2014
15:25 EDTTKMRNew York confirms health care worker being tested for Ebola
Subscribe for More Information
14:58 EDTTKMRNew York doctor rushed to hospital with Ebola-like symptoms, NY Post reports
Subscribe for More Information
11:57 EDTNVSNovartis management to meet with Jefferies
Subscribe for More Information
07:44 EDTARWRArrowhead management to meet with Deutsche Bank
Meetings to be held in Minneapolis/Chicago on October 23 hosted by Deutsche Bank.
06:22 EDTTKMREU to boost Ebola research with EUR 24.4M
The European Commission has today announced EUR 24.4M from the EU budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, the EU research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The Commission is also working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative. The funding will be provided following proposals from teams across the EU and in numerous 3rd countries, which were evaluated by an independent group of experts. The Commission has also asked the European and Developing Countries Clinical Trials Partnership to include emerging epidemics of concern to Africa, including Ebola, in its work plan. This will allow to fund clinical trials on drugs, vaccines and diagnostics in upcoming calls. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
05:21 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies in AS
Novartis announced that AIN457 met primary and key secondary endpoints in two pivotal Phase III studies, MEASURE 1 and MEASURE 2, in patients with ankylosing spondylitis, or AS. Key endpoints included improvements in signs and symptoms of the disease versus placebo and associated improvements in physical function and quality of life. Secukinumab is an investigational medicine that works by stopping the action of interleukin- 17A, a protein that is central to the development of inflammatory diseases, including AS. MEASURE 1 and MEASURE 2 enrolled a combined total of approximately 600 patients. Detailed results of the studies will be presented at an upcoming medical congress. Joint regulatory applications for secukinumab in AS and PsA are planned for 2015. This follows the secukinumab global regulatory applications for moderate- to-severe plaque psoriasis which were filed in October 2013 with regulatory decisions anticipated in late 2014 or early 2015.
October 22, 2014
07:44 EDTNVSGlaxoSmithKline backs FY14 view for core EPS 'broadly similar' to FY13
GlaxoSmithKline (GSK) continues to expect full year 2014 core EPS to be broadly similar to 2013 at CER and on ex-divestment basis. Glaxo says its proposed 3-part transaction with Novartis (NVS) is on track for completion in 1H15.
06:41 EDTTKMRWHO fast-tracking testing of two Ebola vaccines, Guardian reports
Subscribe for More Information
October 21, 2014
19:53 EDTTKMRTekmira commences limited GMP manufacture of Ebola drug
Tekmira Pharmaceuticals provided an update on its Ebola program. The company is reporting it has commenced limited GMP manufacture of a new therapeutic specifically targeting the Ebola, Guinea variant, which is the viral variant responsible for the Ebola epidemic currently prevalent in West Africa. Supply of this new product will be available in early December, for potential use by various collaborators. The Company has completed the design of a modified RNAi therapeutic specifically targeting the Ebola viral variant, now termed 'Ebola-Guinea.' The company's IND for TKM-Ebola remains on partial clinical hold with respect to the multiple ascending dosing in healthy subjects. The company expects this matter to be resolved this quarter.
09:48 EDTTKMR, ALNYShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
07:21 EDTTKMRiBio valuation will be hard to maintain, TheStreet's Feuerstein says
iBio's current valuation will be hard to maintain "even under the best Ebola stockpiling scenario," TheStreet's Adam Feuerstein argues. He notes Ebola related stocks fell yesterday after the quarantines related to Thomas Duncan ended. Reference Link
07:15 EDTNVSFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
15:09 EDTNVSNovartis reports FDA advisory committee recommends approval of secukinumab
Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA voted unanimously to support the approval of AIN457, or secukinumab, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. A Biologics License Application for secukinumab is currently under FDA review with an anticipated action date in early 2015.
09:09 EDTTKMREMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
07:26 EDTNVSFDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
October 19, 2014
16:44 EDTTKMREbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTTKMRCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTTKMR, NVSBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTTKMRSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use